SEARCH

SEARCH BY CITATION

References

  • AZZI, M., CHAREST, P.G., ANGERS, S., ROSSEAU, G., KOHOUT, T., BOUVIER, M. & PINERYO, G. (2003). Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A., 100, 1140611411.
  • AZZI, M., PINERYO, G., PONTIER, S., PARENT, S., ANSANAY, H. & BOUVIER, M. (2001). Allosteric effects of G protein overexpression on the binding of β-adrenergic ligands with distinct inverse effacacies. Mol. Pharmacol., 60, 9991007.
  • BAKER, J.G., HALL, I.P. & HILL, S.J. (2002). Pharmacological characterization of CGP 12177 at the human β2-adrenoceptor. Br. J. Pharmacol., 137, 400408.
  • BAKER, J.G., HALL, I.P. & HILL, S.J. (2003a). Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses. Mol. Pharmacol., 64, 679688.
  • BAKER, J.G., HALL, I.P. & HILL, S.J. (2003b). Agonist actions of ‘β-blockers’ provide evidence for two agonist activation sites or conformations of the human β1-adrenoceptor. Mol. Pharmacol., 63, 13121321.
  • BAKER, J.G., HALL, I.P. & HILL, S.J. (2003c). Agonist and inverse agonist actions of β-blockers at the human β2-adrenoceptor provide evidence for agonist-directed signalling. Mol. Pharmacol., 64, 13571369.
  • Beta-blocker Evaluation of Survival Trial Investigators (BEST) (2001). A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med., 344, 16591667.
  • BLACK, J.W., DUNCAN, W.A.M. & SHANKS, R.G. (1965). Comparison of some properties of pronethalol and propranolol. Br. J. Pharmacol., 25, 577591.
  • BOND, R.A., LEFF, P., JOHNSON, T.D., MILANO, C.A., ROCKMAN, H.A., MCMINN, T.R., APPARSUNDARAM, S., HYEK, M.F., KENAKIN, T., ALLEN, L.F. & LEFKOWITZ, R.J. (1995). Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β2-adrenoceptor. Nature, 374, 272276.
  • CHIDIAC, P., HEBERT, T.E., VALIQUETTE, M., DENNIS, M. & BOUVIER, M. (1994). Inverse agonist activity of β-adrenergic antagonists. Mol. Pharmacol., 45, 490499.
  • CIBIS-II (1999). Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet, 353, 913.
  • COMET:POOLE-WILSON, P.A., SWEDBERG, K., CLELAND, J.G., DI LENARDA, A., HANRATH, P., KOMAJDA, M., LUBSEN, J., LUTIGER, B., METRA, M., REMME, W.J., TORP-PEDERSEN, C., SCHERHAG, A, SKENE, A. & CARVEDILOL OR METOPR (2003). Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 362, 713.
  • FEELY, J. & PEDEN, N. (1984). Use of beta-adrenoceptor blocking drugs in hyperthyroidism. Drugs, 27, 425446.
  • HARMS, H.H. (1976). Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: a comparative study of human and guinea-pig cardiac and bronchial beta adrenergic receptors. J. Pharmacol. Exp. Ther., 199, 329335.
  • HEIDENREICH, P.A., MCDONALD, K.M., HASTIE, T., FADEL, B., HAGAN, V., LEE, B.K. & HLATKY, M.A. (1999). Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. J. Am. Medic. Assoc., 281, 19271936.
  • HOFFMANN, C., LEITZ, M.R., OBERDORF-MAASS, S., LOHSE, M.J. & KLOTZ, K.N. (2004). Comparative pharmacology of human β-adrenergic receptor subtypes – characterization of stably transfected receptor in CHO cells. Naunyn-Schmiedeberg's Arch. Pharmacol., 369, 151159.
  • JASPER, J.R., MICHEL, M.C. & INSEL, P.A. (1990). Amplification of cyclic AMP generation reveals agonistic effects of certain beta-adrenergic antagonists. Mol. Pharmacol., 37, 4449.
  • KOBILKA, B. (1992). Adrenergic receptors as models for G protein-coupled receptor. Annu. Rev. Neurosci., 15, 87114.
  • LEWIS, R.V. & LOFTHOUSE, C. (1993). Adverse reactions with beta-adrenoceptor blocking drugs. An update. Drug Saf., 9, 272279.
  • LIANG, W. & MILLS, S. (2001). Profile of ligand binding to the porcine β2-adrenergic receptor. J. Anim. Sci., 79, 877883.
  • LIMMROTH, V. & MICHEL, M.C. (2001). The prevention of migraine: a critical review with special emphasis of β-adrenergic blockers. Br. J. Clin. Pharmacol., 52, 237243.
  • PEET, M. & YATES, R.A. (1981). Beta-blockers in the treatment of neurological and psychiatric disorders. J. Clin. Hosp. Pharm., 6, 155171.
  • PRICHARD, B.N. (1988). Beta-blockade therapy and cardiovascular disease. Past, present and future. Postgrad. Med., 29, 818.
  • PRICHARD, B.N., CRUICKSHANK, J.M. & GRAHAM, B.R. (2001). Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press., 10, 366386.
  • SMITH, C. & TEITLER, M. (1999). Beta-blocker selectivity at cloned human beta1- and beta2-adrenoceptors. Cardiovasc. Drugs Ther., 13, 123126.
  • STAMPER, R.L., WIGGINGTON, S.A. & HIGGINBOTHAM, E.J. (2002). Primary drug treatment for glaucoma: beta-blocker versus other medications. Surv. Ophthalmol., 47, 6367.
  • UITTI, R.J. (1998). Medical treatment of essential tremor and Parkinson's disease. Geriatrics, 53, 4648, 53–57.